Alovudine

This classification denotes a reverse transcriptase inhibitor with the molecular formula C10H13FN2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PG53R0DWDQ, chemically known as thymidine, 3-deoxy-3-fluoro- but generally known as alovudine, which bears US NIH Compound Identifier 33039. European Medicines Agency schedules Alovudine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05359MIG. The term ALOVUDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 7, No3, 1993, List 33). ALOVUDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule alovudine under HS 29349990 and SITC 51579. As of Q4 2014, ALOVUDINE remains the US FDA Preferred Term for this commodity. Alovudine bears US NLM identifiers UMLS ID C0206795 and NCI Concept Code C65226. SMILES: CC1=CN(C(=O)NC1=O)C2CC(C(O2)CO)F.